Thrombosis as an intravascular effector of innate immunity

被引:1329
|
作者
Engelmann, Bernd [1 ]
Massberg, Steffen [2 ,3 ]
机构
[1] Univ Munich, Inst Lab Med, D-81377 Munich, Germany
[2] Univ Munich, Med Klin & Poliklin 1, D-81377 Munich, Germany
[3] Munich Heart Alliance, Munich, Germany
关键词
NEUTROPHIL EXTRACELLULAR TRAPS; PROTEIN DISULFIDE-ISOMERASE; DEEP-VEIN THROMBOSIS; TISSUE FACTOR CONTRIBUTES; COAGULATION-FACTOR-XII; VON-WILLEBRAND-FACTOR; IN-VIVO; VENOUS THROMBOSIS; PLATELET-ADHESION; BLOOD-COAGULATION;
D O I
10.1038/nri3345
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Thrombosis is the most frequent cause of mortality worldwide and is closely linked to haemostasis, which is the biological mechanism that stops bleeding after the injury of blood vessels. Indeed, both processes share the core pathways of blood coagulation and platelet activation. Here, we summarize recent work suggesting that thrombosis under certain circumstances has a major physiological role in immune defence, and we introduce the term immunothrombosis to describe this process. Immunothrombosis designates an innate immune response induced by the formation of thrombi inside blood vessels, in particular in microvessels. Immunothrombosis is supported by immune cells and by specific thrombosis-related molecules and generates an intravascular scaffold that facilitates the recognition, containment and destruction of pathogens, thereby protecting host integrity without inducing major collateral damage to the host. However, if uncontrolled, immunothrombosis is a major biological process fostering the pathologies associated with thrombosis.
引用
收藏
页码:34 / 45
页数:12
相关论文
共 50 条
  • [21] Crossroads of coagulation and innate immunity: the case of deep vein thrombosis
    Schulz, C.
    Engelmann, B.
    Massberg, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 233 - 241
  • [22] Moonlighting proteins dictate the crosstalk between thrombosis and innate immunity
    Saffarzadeh, M.
    Preissner, K. T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (12) : 2070 - 2073
  • [23] The first line of defense: effector pathways of anti-fungal innate immunity
    Ward, Rebecca A.
    Vyas, Jatin M.
    CURRENT OPINION IN MICROBIOLOGY, 2020, 58 : 160 - 165
  • [24] Pseudomonas syringae effector AvrPto blocks innate immunity by targeting receptor kinases
    Xiang, Tingting
    Zong, Na
    Zou, Yan
    Wu, Yong
    Zhang, Jie
    Xing, Weiman
    Li, Yan
    Tang, Xiaoyan
    Zhu, Lihuang
    Chai, Jijie
    Zhou, Jian-Min
    CURRENT BIOLOGY, 2008, 18 (01) : 74 - 80
  • [25] Effector-triggered innate immunity contributes Arabidopsis resistance to Xanthomonas campestris
    Rong, Wei
    Feng, Feng
    Zhou, Jianmin
    He, Chaozu
    MOLECULAR PLANT PATHOLOGY, 2010, 11 (06) : 783 - 793
  • [26] The 3 major types of innate and adaptive cell-mediated effector immunity
    Annunziato, Francesco
    Romagnani, Chiara
    Romagnani, Sergio
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (03) : 626 - 635
  • [27] Interleukin-17 as an effector molecule of innate and acquired immunity against infections
    Matsuzaki, Goro
    Umemura, Masayuki
    MICROBIOLOGY AND IMMUNOLOGY, 2007, 51 (12) : 1139 - 1147
  • [28] Effector specificity and function in Drosophila innate immunity: Getting AMPed and dropping Boms
    Lin, Samuel J. H.
    Cohen, Lianne B.
    Wasserman, Steven A.
    PLOS PATHOGENS, 2020, 16 (05)
  • [29] Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study
    Reitsma, PH
    Rosendaal, FR
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (04) : 619 - 622
  • [30] Adaptive innate immunity or innate adaptive immunity?
    Cerny, Jan
    Striz, Ilja
    CLINICAL SCIENCE, 2019, 133 (14) : 1549 - 1565